Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of OSI-211 Vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
This study has been completed.
Study NCT00046800   Information provided by OSI Pharmaceuticals
First Received: October 3, 2002   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
OSI-211 (Liposomal Lurtotecan)
Additional drug interventions recognized in this trial
Lurtotecan
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
OSI Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services